

Development of monoclonal antibodies to prevent and treat infections from Flaviviruses

Horizon Europe

● PENDING

Code

HORIZON-HLTH-2027-01-DISEASE-06

Scope

International

Location

Europe

Curator

Marlene Faria

FINANCIAL DETAILS

Support type

Non-Refundable

Maximum Funding Rate

100%

Budget

37.3M€

Eligible Project Value

Up to 10M€

DATES & DEADLINES

Publication Date

October 16, 2026

Opening Date

October 29, 2026

Fase única

February 17, 2027 at 05:00 PM GMT+1

DESCRIPTION

Objectives

This topic aims to advance existing prophylactic and therapeutic monoclonal antibody candidates against emerging and re-emerging Flavivirus infections. The objective is to make experimental antibodies available for further clinical development and increase the number of treatment options that could be rapidly deployed during future epidemics or pandemics. The topic also supports the implementation of the European Medical Countermeasures Strategy and seeks to strengthen European leadership and preparedness in antiviral research and development.

Funding

Funding is provided under a Horizon Europe Research and Innovation Action (RIA). The topic has an indicative budget of €37.3 million, with approximately four projects expected to be funded. The anticipated EU contribution ranges from €9 million to €10 million per project, although proposals requesting different

amounts may be considered where appropriately justified. As an RIA, the action may receive funding of up to 100% of eligible costs, in accordance with Horizon Europe rules.

ELIGIBLE EXPENSES

- Personnel Costs
- Travel costs
- Equipment costs
- Other goods, works and services costs
- Subcontracting
- Indirect Costs

ELIGIBILITY

Eligible Sectors

Health & Life Sciences

Application Mode

Consortium / Copromotion

Company Typologies

- Micro
- SME
- Small Mid-Cap
- Mid-Cap
- Large
- Non-business entities of the R&I system (ENESII)
- Private non-profit entities
- Public entities

Action Types

- Research and Innovation Action
- Collaborative Project

EU PROGRAMME DETAILS

Call ID

HORIZON-HLTH-2027-01-DISEASE-06

Cluster

Health

Destination

D3. Tackling diseases and reducing disease burden

Submission Mode

Single-stage

EU Contribution

Around €9,000,000.00 to €10,000,000.00 per project

Expected Projects

4

Funding Rate Rule

Up to 100% of eligible costs for Research and Innovation Actions (RIA)

OFFICIAL LINKS

Official Regulation

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2027-01-DISEASE-06?order=DESC&pageNumber=1&pageSize=50&sortBy=startDate&keywords=HORIZON-HLTH-2027-01-DISEASE-06&isExactMatch=true&status=31094501,31094502,31094503>

Grantavia page

<https://grantavia.com/en/incentives/development-of-monoclonal-antibodies-to-prevent-and-treat-infections-from-flaviviruses>

Schedule a meeting

<https://calendly.com/sandra-cardoso-epsa/reuniao>